United States in Vitro Diagnostics Investment Opportunities

Analysis and Forecasts to 2015

Product Code GMD07384
Publication Date April 2009
Publisher Global Markets Direct
Product Type Report
Pages 234
ISBN Number not applicable
Change currency
PDF £1,580.00 €1,903 $2,498 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

United States in Vitro Diagnostics Investment Opportunities

Analysis and Forecasts to 2015

This report is an essential source for in-depth information and data relating to the USA In vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in USA

Scope

  • The report provides in vitro diagnostics information broken down into detailed categories and segments in United States.
  • Total revenues, end users
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the in vitro diagnostics devices market in United States.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 List of Tables
  • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of Markets Covered in This Report
    • 3.1 In Vitro Diagnostics
    • 3.2 Clinical Chemistry Test Reagents
    • 3.3 Immunochemistry Test Reagents
    • 3.4 Blood Test Reagents
    • 3.5 Microbiology Test Reagents
    • 3.6 Infectious Immunology Test Reagents
    • 3.7 Genetic Test Reagents
    • 3.8 Self Testing
    • 3.9 Instruments
  • 4 Healthcare Sector Review
    • 4.1 Healthcare Expenditure
    • 4.2 Healthcare Infrastructure
    • 4.3 United States Healthcare Trade Statistics
  • 5 Regulation System
    • 5.1 Regulation System
    • 5.2 Medical Equipment Approval Process
  • 6 Pricing and Reimbursement
    • 6.1 Government Policies
    • 6.2 Private Insurance
    • 6.3 Diagnosis Related Groups (DRG)
  • 7 Distribution Structure
    • 7.1 Distribution Structure
  • 8 In Vitro Diagnostics In United States
    • 8.1 In Vitro Diagnostics Cross Country Comparison, Revenue ($ mn), 2000-2015
    • 8.2 In Vitro Diagnostics, United States, Overall Revenue ($ mn), 2000-2015
    • 8.3 In Vitro Diagnostics, United States, Company Share (2006-2007)
  • 9 Blood Test Reagents In United States
    • 9.1 Blood Test Reagents Overall Revenue (2000-2015)
    • 9.2 Blood Test Reagents Distribution Share (2007-2008)
    • 9.3 Blood Test Reagents, United States, Company Share (2006-2007)
  • 10 Clinical Chemistry Test Reagents In United States
    • 10.1 Clinical Chemistry Test Reagents Overall Revenue (2000-2015)
    • 10.2 Clinical Chemistry Test Reagents Distribution Share (2007-2008)
    • 10.3 Clinical Chemistry Test Reagents, United States, Company Share (2006-2007)
  • 11 Genetic Test Reagents In United States
    • 11.1 Genetic Test Reagents Overall Revenue (2000-2015)
    • 11.2 Genetic Test Reagents Distribution Share (2007-2008)
    • 11.3 Genetic Test Reagents, United States, Company Share (2006-2007)
  • 12 Immunochemistry Test Reagents In United States
    • 12.1 Immunochemistry Test Reagents Overall Revenue (2000-2015)
    • 12.2 Immunochemistry Test Reagents Distribution Share (2007-2008)
    • 12.3 Immunochemistry Test Reagents, United States, Company Share (2006-2007)
  • 13 Infectious Immunology Test Reagents In United States
    • 13.1 Infectious Immunology Test Reagents Overall Revenue (2000-2015)
    • 13.2 Infectious Immunology Test Reagents Distribution Share (2007-2008)
    • 13.3 Infectious Immunology Test Reagents, United States, Company Share (2006-2007)
  • 14 Instruments In United States
    • 14.1 Instruments Overall Revenue (2000-2015)
    • 14.2 Instruments Distribution Share (2007-2008)
  • 15 Microbiology Test Reagents In United States
    • 15.1 Microbiology Test Reagents Overall Revenue (2000-2015)
    • 15.2 Microbiology Test Reagents Distribution Share (2007-2008)
    • 15.3 Microbiology Test Reagents, United States, Company Share (2006-2007)
  • 16 Self Testing In United States
    • 16.1 Self Testing Overall Revenue (2000-2015)
    • 16.2 Self Testing Distribution Share (2007-2008)
    • 16.3 Self Testing, United States, Company Share (2006-2007)
  • 17 Overview of Key Companies in United States In Vitro Diagnostics Market
    • 17.1 F. Hoffmann-La Roche Ltd. Company Profile
    • 17.2 Beckman Coulter, Inc. Company Profile
    • 17.3 Dade Behring Holdings, Inc. Company Profile
    • 17.4 Abbott Laboratories Company Profile
    • 17.5 Siemens Healthcare Company Profile
    • 17.6 Becton, Dickinson and Company Profile
    • 17.7 Gen-Probe Incorporated Company Profile
    • 17.8 bioMerieux S.A. Company Profile
    • 17.9 Genzyme Corporation Company Profile
    • 17.10 OLYMPUS CORPORATION Company Profile
    • 17.11 Ventana Medical Systems, Inc. Company Profile
    • 17.12 Digene Corporation Company Profile
  • 18 Financial Deals Landscape
    • 18.1 Merger
    • 18.2 Acquisition
    • 18.3 Partnerships
  • 19 Recent Developments
    • 19.1 Strategy and Business Planning
    • 19.2 Legal and Regulatory
    • 19.3 Government and Public Interest
    • 19.4 Product News
  • 20 Appendix
    • 20.1 Global Markets Direct Research Methodology
    • 20.2 Coverage
    • 20.3 Secondary Research
    • 20.4 Primary Research
    • 20.5 Models
    • 20.6 Forecasts
    • 20.7 Expert Panel Validation
    • 20.8 Currency Conversion
    • 20.9 Contact Us
    • 20.10 Disclaimer
  • 1 List of Tables
    • Table 1: United States Healthcare Expenditure, 2003-2010
    • Table 2: United States Healthcare Expenditure by Age (per person), 2000-2003
    • Table 3: United States Healthcare Expenditure by Sex (per person), 2000-2003
    • Table 4: United States Healthcare Expenditure by Race (per person), 2000-2003
    • Table 5: United States Personal Healthcare Expenditure by Type, 2000-2004
    • Table 6: United States Personal Healthcare Expenditure by Source, 2000-2004
    • Table 7: Total Number of Doctors in the United States, 2003-2010
    • Table 8: Number of Doctors by Specialty in the United States, 2003-2010
    • Table 9: Doctors by Region (Number per 10,000 Civilian Population), 2002-2004
    • Table 10: Doctors by Region (Number per 10,000 Civilian Population), 2002-2004 (Cont.)
    • Table 11: Total Hospitals in the United States, 2000-2004
    • Table 12: Community Hospitals by Number of Beds in the United States, 2000-2004
    • Table 13: Number of Hospital Beds in the United States, 2000-2004
    • Table 14: Number of Hospital Beds by Range in the United States, 2000-2004
    • Table 15: United States Healthcare Trade Statistics, 2001-2006
    • Table 16: Medical Equipment Registration Fee in United States, 2007
    • Table 17: Medical Device Approval Time in United States, 2004
    • Table 18: In Vitro Diagnostics Cross Country Comparison, Revenue ($ mn), 2000-2015
    • Table 19: In Vitro Diagnostics, United States, Overall Revenue ($ mn), 2000-2015
    • Table 20: In Vitro Diagnostics, United States, Cross-Category Analysis, 2000-2015
    • Table 21: In Vitro Diagnostics, United States, Overall Revenue ($ mn), Historic, 2000-2008
    • Table 22: In Vitro Diagnostics, United States, Overall Revenue ($ mn), Forecast, 2008-2015
    • Table 23: In Vitro Diagnostics, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 24: Blood Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 25: Blood Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 26: Haematology Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 27: Haematology Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 28: Hemostasis Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 29: Hemostasis Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 30: Blood Test Reagents, United States, Distribution Share by Revenue ($mn), 2007-2008
    • Table 31: Blood Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 32: Clinical Chemistry Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 33: Clinical Chemistry Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 34: Clinical Chemistry Test Reagents, United States, Distribution Share by Revenue ($mn), 2007-2008
    • Table 35: Clinical Chemistry Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 36: Genetic Test Reagents, United States, Revenue ($ mn), Historic, 2000-2008
    • Table 37: Genetic Test Reagents, United States, Revenue ($ mn), Forecast, 2008-2015
    • Table 38: Genetic Test Reagents, United States, Distribution Share by Revenue ($mn), 2007-2008
    • Table 39: Genetic Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 40: Immunochemistry Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 41: Immunochemistry Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 42: Disease Specific Markers, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 43: Disease Specific Markers, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 44: Disease Specific Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 45: Disease Specific Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 46: Drug Related Testing Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 47: Drug Related Testing Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 48: Hormone Related Testing Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 49: Hormone Related Testing Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 50: Immunochemistry Test Reagents, United States, Distribution Share by Revenue ($mn), 2007-2008
    • Table 51: Immunochemistry Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 52: Infectious Immunology Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 53: Infectious Immunology Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 54: Virology, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 55: Virology, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 56: Infectious Immunology Test Reagents, United States, Distribution Share by Revenue ($mn), 2007-2008
    • Table 57: Infectious Immunology Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 58: Instruments, United States, Revenue ($ mn), Historic, 2000-2008
    • Table 59: Instruments, United States, Revenue ($ mn), Forecast, 2008-2015
    • Table 60: Instruments, United States, Distribution Share by Revenue ($mn), 2007-2008
    • Table 61: Microbiology Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Table 62: Microbiology Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Table 63: Bacteriology Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Table 64: Bacteriology Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Table 65: Microbiology Test Reagents, United States, Distribution Share by Revenue ($mn), 2007-2008
    • Table 66: Microbiology Test Reagents, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 67: Self Testing, United States, Revenue ($ mn), Historic, 2000-2008
    • Table 68: Self Testing, United States, Revenue ($ mn), Forecast, 2008-2015
    • Table 69: Self Testing, United States, Distribution Share by Revenue ($mn), 2007-2008
    • Table 70: Self Testing, United States, Company Share by Revenue ($ mn), 2006-2007
    • Table 71: Beckman Coulter, Inc. Pipeline Products by Equipment Type
    • Table 72: Beckman Coulter, Inc. Pipeline Products By Development Stage
    • Table 73: Beckman Coulter, Inc. Pipeline Products By Therapy Area
    • Table 74: Beckman Coulter, Inc. Pipeline Products By News Summary
    • Table 75: Gen-Probe Incorporated Pipeline Products by Equipment Type
    • Table 76: Gen-Probe Incorporated Pipeline Products By Development Stage
    • Table 77: Gen-Probe Incorporated Pipeline Products By Therapy Area
    • Table 78: Gen-Probe Incorporated Pipeline Products By Clinical Trials
    • Table 79: Gen-Probe Incorporated Pipeline Products By News Summary
    • Table 80: Genzyme Corporation Pipeline Products by Equipment Type
    • Table 81: Genzyme Corporation Pipeline Products By Development Stage
    • Table 82: Genzyme Corporation Pipeline Products By Therapy Area
    • Table 83: Genzyme Corporation Pipeline Products By Clinical Trials
    • Table 84: Genzyme Corporation Pipeline Products By News Summary
    • Table 88: Olympus Medical Systems Corp. Pipeline Products by Equipment Type
    • Table 89: Olympus Medical Systems Corp. Pipeline Products by Development Stage
    • Table 90: Olympus Medical Systems Corp. Pipeline Products by Therapy Area
    • Table 91: Olympus Medical Systems Corp. Pipeline Products by Clinical Trials
    • Table 92: Olympus Medical Systems Corp. Pipeline Products by News Summary
    • Table 93: Nanobac Pharmaceuticals To Merge With Eureka Genomics
    • Table 94: Bookham To Merge With AVANEX
    • Table 95: Invitrogen Merges With Applied Biosystems To Form Life Technologies
    • Table 96: Sekisui Chemical To Acquire American Diagnostica
    • Table 97: Enzo Biochem Acquires Assay Designs
    • Table 98: Arcxis Biotechnologies Receives Investment From In-Q-Tel
    • Table 99: Mediscience Technology Acquires SensiVida Medical Systems
    • Table 100: SEQUENOM Acquires SensiGen
    • Table 101: Tri-Star Holdings Acquires Lyfetec
    • Table 102: Millipore To Acquire Guava Technologies
    • Table 103: Cantimer Receives Equity Investment Of $1 Million From Advanced Instruments
    • Table 104: SEQUENOM Terminates Its Offer To Acquire EXACT Sciences
    • Table 105: Genzyme Acquires Minority Stake In EXACT Sciences
    • Table 106: Metametrix Clinical Laboratory Acquires Accu-Chem Laboratories
    • Table 107: Neogenix Oncology Acquires International Bio Immune Systems
    • Table 108: Abbott Laboratories Acquires Ibis Biosciences From Isis Pharmaceuticals
    • Table 109: Nuvera Biosciences Enters Into An Agreement With Veridex
    • Table 110: Idaho Technology Enters Into An Agreement With Thermo Fisher Scientific
    • Table 111: Mediwatch Enters Into An Agreement With Inverness Medical Innovations
    • Table 112: Spectral Diagnostics Signs A Licensing Agreeement With Toray Industries
    • Table 113: Nanogen Enters Into An Agreement With Quest Diagnostics
    • Table 114: Nanogen Enters Into An Agreement With HandyLab
    • Table 115: Epigenomics Enters Into An Agreement With Quest Diagnostics
    • Table 116: Innovative Biosensors Enters Into An Agreement With ProGenTech
    • Table 117: CytoCore Enters Into An Agreement With Synermed Select Partners
    • Table 118: Vista Therapeutics Signs An Agreement With Harvard University And Nanosys
    • Table 119: Ceapro Enters Into An Agreement With IR2Dx
    • Table 120: Health Discovery Signs An Agreement With Quest Diagnostics
    • Table 121: Health Discovery Signs An Agreement With Abbott Laboratories
    • Table 122: Biofield Signs A Distribution Agreement
    • Table 123: Nanogen Signs An Agreement With Scandinavian Gene Synthesis
    • Table 124: Transgenomic Signs An Agreement With Power3 Medical Products
    • Table 125: QuantRx Biomedical Signs An Agreement With Church & Dwight
    • Table 126: Artemis Health Enters Into An Agreement With Stanford University
    • Table 127: Combimatrix Molecular Diagnostics Enters Into An agreement With Lenetix
    • Table 128: Evogen Enters Into An Agreement With LGC
    • Table 129: Rubicon Genomics Enters Into An Agreement With Abbott Laboratories
    • Table 130: Illumina Enters Into An Agreement With Oxford Nanopore Technologies
    • Table 131: USD to Local Currency, Average Exchange Rate 2008
  • 1.2 List of Figures
    • Figure 1: United States, Healthcare Expenditure by Source, 2003
    • Figure 2: United States, Healthcare Infrastructure, Top Level View, 2007
    • Figure 3: Healthcare Expenses Segmentation by End User, 2003
    • Figure 4: Medical Equipment Approval Process in the United States, 2007
    • Figure 5: PMA Approval Process in the United States, 2007
    • Figure 6: The 510(k) Approval Process for Medical Devices in the United States, 2007
    • Figure 7: Reimbursement Structure in the United States, 2007
    • Figure 8: Distribution Structure of Medical Equipment in the United States, 2006
    • Figure 9: In Vitro Diagnostics Cross Country Comparison, Revenue ($ mn), 2000-2015
    • Figure 10: In Vitro Diagnostics, United States, Overall Revenue ($ mn), 2000-2015
    • Figure 11: In Vitro Diagnostics, United States, Cross-Category Analysis, 2000-2015
    • Figure 12: In Vitro Diagnostics, United States, Overall Revenue ($ mn), Historic, 2000-2008
    • Figure 13: In Vitro Diagnostics, United States, Overall Revenue ($ mn), Forecast, 2008-2015
    • Figure 14: In Vitro Diagnostics, United States, Company Share (%), 2007
    • Figure 15: Blood Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 16: Blood Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 17: Haematology Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 18: Haematology Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 19: Hemostasis Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 20: Hemostasis Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 21: Blood Test Reagents, United States, Company Share (%), 2007
    • Figure 22: Clinical Chemistry Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 23: Clinical Chemistry Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 24: Clinical Chemistry Test Reagents, United States, Company Share (%), 2007
    • Figure 25: Genetic Test Reagents, United States, Revenue ($ mn), Historic, 2000-2008
    • Figure 26: Genetic Test Reagents, United States, Revenue ($ mn), Forecast, 2008-2015
    • Figure 27: Genetic Test Reagents, United States, Company Share (%), 2007
    • Figure 28: Immunochemistry Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 29: Immunochemistry Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 30: Disease Specific Markers, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 31: Disease Specific Markers, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 32: Disease Specific Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 33: Disease Specific Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 34: Drug Related Testing Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 35: Drug Related Testing Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 36: Hormone Related Testing Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 37: Hormone Related Testing Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 38: Immunochemistry Test Reagents, United States, Company Share (%), 2007
    • Figure 39: Infectious Immunology Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 40: Infectious Immunology Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 41: Virology, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 42: Virology, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 43: Infectious Immunology Test Reagents, United States, Company Share (%), 2007
    • Figure 44: Instruments, United States, Revenue ($ mn), Historic, 2000-2008
    • Figure 45: Instruments, United States, Revenue ($ mn), Forecast, 2008-2015
    • Figure 46: Microbiology Test Reagents, United States, Revenue ($ mn) by Segment, Historic, 2000-2008
    • Figure 47: Microbiology Test Reagents, United States, Revenue ($ mn) by Segment, Forecast, 2008-2015
    • Figure 48: Bacteriology Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008
    • Figure 49: Bacteriology Test Reagents, United States, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015
    • Figure 50: Microbiology Test Reagents, United States, Company Share (%), 2007
    • Figure 51: Self Testing, United States, Revenue ($ mn), Historic, 2000-2008
    • Figure 52: Self Testing, United States, Revenue ($ mn), Forecast, 2008-2015
    • Figure 53: Self Testing, United States, Company Share (%), 2007
    • Figure 54: F. Hoffmann-La Roche Ltd Value Chain Analysis
    • Figure 55: Beckman Coulter, Inc. Value Chain Analysis
    • Figure 56: Abbott Laboratories Value Chain Analysis
    • Figure 57: Siemens Medical Solutions Value Chain Analysis
    • Figure 58: Becton, Dickinson and Company Value Chain Analysis
    • Figure 59: Gen-Probe Incorporated Value Chain Analysis
    • Figure 60: Biomerieux Sa Value Chain Analysis
    • Figure 62: Olympus Medical Systems Corp. Value Chain Analysis
    • Figure 63: Global Markets Direct Methodology